Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Even With No Disease Activity, Recurrence Risk Near 50% When Stopping DMTs for MS

Publish date:: October 1, 2019

Key clinical point: A small cohort of patients with CIS meeting MS diagnostic criteria stopped DMT after 5 years of no disease activity, and just under half had MS recurrence.

Major finding: Of the cohort of 46 patients, 23 had disease recurrence, with recurrence more likely among younger patients.

Study details: Cohort study of 46 patients with initial clinical episode of MS, meeting Barkhof criteria for MS on magnetic resonance imaging.

Disclosures: The authors reported no conflicts of interest. No external sources of funding were reported.

Citation:

Monschein T et al. ECTRIMS 2019. Abstract P654.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,